AstraZeneca has announced a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on novel treatments for rare endocrine diseases, in a deal valued at up to $1.05 billion. This acquisition is poised to strengthen the late-stage pipeline of Alexion, AstraZeneca Rare Disease, particularly bolstering its bone metabolism franchise through the addition of […]
Soliris (eculizumab), the first and only targeted therapy approved for the treatment of paediatric patients with refractory generalised myasthenia gravis (gMG), from Alexion, AstraZeneca Rare Disease has obtained approval for expanded use in the European Union (EU). The approval allows the treatment of gMG in children and adolescents aged six to 17 years who are […]
Alexion, a subdivision of AstraZeneca focusing on rare diseases, has announced its definitive purchase and licensing agreement for a portfolio of preclinical gene therapy programmes from Pfizer Inc. The deal, a move to strengthen Alexion and AstraZeneca’s commitment to next-generation genomic medicines, is worth up to $1 billion, plus tiered royalties on sales. This acquisition […]
Alexion, AstraZeneca Rare Disease has agreed to acquire LogicBio Therapeutics, an American clinical-stage genetic medicine company in a deal worth $68 million. As per the terms of the deal, shareholders of the NASDAQ-listed LogicBio Therapeutics will be paid $2.07 per share by Alexion, AstraZeneca Rare Disease. The latter was formed following last year’s $39 billion […]